NASDAQ:CASI

CASI Pharmaceuticals (CASI) Stock Forecast, Price & News

$2.13

+0.13 (+6.50%)

(As of 09/26/2023 ET)

Compare

Today's Range: $2.03
▼
$2.15
50-Day Range: $2.00
▼
$2.74
52-Week Range: $1.45
▼
$3.70

Volume: 8,564 shs
Average Volume: N/A
Market Capitalization: $28.37 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $10.00

CASI Pharmaceuticals MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 369.5% Upside
$10.00 Price Target
Short Interest: Healthy
3.56% of Float Sold Short
Dividend Strength: N/A
Sustainability: -1.50
Upright™ Environmental Score
News Sentiment: 0.00
Based on 2 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($2.23) to ($0.57) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.25 out of 5 stars

Medical Sector

340th out of 963 stocks

Biological Products, Except Diagnostic Industry

52nd out of 155 stocks

3.5

Analyst's Opinion

Consensus Rating
CASI Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $10.00, CASI Pharmaceuticals has a forecasted upside of 369.5% from its current price of $2.13.
Amount of Analyst Coverage
CASI Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
3.56% of the float of CASI Pharmaceuticals has been sold short.
Short Interest Ratio / Days to Cover
CASI Pharmaceuticals has a short interest ratio ("days to cover") of 9.1.
Change versus previous month
Short interest in CASI Pharmaceuticals has recently decreased by 1.41%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
CASI Pharmaceuticals does not currently pay a dividend.
Dividend Growth
CASI Pharmaceuticals does not have a long track record of dividend growth.

4.3

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
CASI Pharmaceuticals has received a 62.54% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Melphalan" and "Clinical research services for cancer" products. See details.
Environmental Sustainability
The Environmental Impact score for CASI Pharmaceuticals is -1.50.

0.6

News and Social Media Coverage

News Coverage This Week
MarketBeat has tracked 2 news articles for CASI Pharmaceuticals this week, compared to 0 articles on an average week.
MarketBeat Follows
2 people have added CASI Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, CASI Pharmaceuticals insiders have not sold or bought any company stock.
Percentage Held by Insiders
21.24% of the stock of CASI Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 14.62% of the stock of CASI Pharmaceuticals is held by institutions.

1.3

Earnings and Valuation

Earnings Growth
Earnings for CASI Pharmaceuticals are expected to grow in the coming year, from ($2.23) to ($0.57) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of CASI Pharmaceuticals is -0.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of CASI Pharmaceuticals is -0.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
CASI Pharmaceuticals has a P/B Ratio of 0.65. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About CASI Pharmaceuticals (NASDAQ:CASI) Stock

CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in the People's Republic of China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation, and as a palliative treatment for patients with multiple myeloma. The company's other hematology/oncology assets in pipeline include CNCT 19, an autologous CD19 CAR-T investigative product; BI-1206, novel anti-Fc?RIIB antibody, for the treatment of solid tumors and relapsed/refractory non-hodgkin lymphoma; CB-5339, a novel VCP/p97 inhibitor that focuses on valosin-containing protein (VCP)/p97 as a novel target in protein homeostasis, DNA damage response, and other cellular stress pathways for therapeutic use in the treatment of patients with various malignancies; and CID-103, a human IgG1 anti-CD38 monoclonal antibody. The company has licensing agreements with Juventas Biotechnology (Tianjin) Co., Ltd.; BioInvent International AB; Black Belt Therapeutics Limited; Cleave Therapeutics, Inc.; and Acrotech Biopharma L.L.C. to develop and commercialize its commercial product EVOMELA. It also has distribution agreements with China Resources Pharmaceutical Commercial Group International Trading Co., Ltd; Pharmathen Global BV; and Riemser Pharma GmbH. CASI Pharmaceuticals, Inc. was incorporated in 1991 and is based in Beijing, the People's Republic of China.

CASI Price History

30 days | 90 days | 365 days | Advanced Chart

CASI Stock News Headlines

September 26, 2023 | americanbankingnews.com

CASI Pharmaceuticals (NASDAQ:CASI) Now Covered by Analysts at StockNews.com

September 18, 2023 | americanbankingnews.com

CASI Pharmaceuticals (NASDAQ:CASI) Coverage Initiated by Analysts at StockNews.com

September 27, 2023 | Wall Street Fundamentals (Ad)

The "Plug and Play" Model Putting Online Giants to Shame

While e-commerce has been undergoing a turbulent time, a "simple" model has grown 4X faster than Amazon over the last 3 years. Applying this model to high-margin, recession-resistant businesses has shown to be profitable. But that's just the beginning of explaining the 400+% growth - and potential - of this "diamond in the rough."

August 14, 2023 | markets.businessinsider.com

H.C. Wainwright Sticks to Its Buy Rating for CASI Pharmaceuticals (CASI)

August 11, 2023 | markets.businessinsider.com

CASI Pharmaceuticals, Inc. Q2 Loss Widens

August 11, 2023 | msn.com

CASI Pharmaceuticals GAAP EPS of -$0.77, revenue of $9.82M

August 11, 2023 | finance.yahoo.com

CASI PHARMACEUTICALS ANNOUNCES SECOND QUARTER 2023 BUSINESS AND FINANCIAL UPDATES

August 10, 2023 | msn.com

Ionis Pharmaceuticals (IONS) Q2 Earnings and Revenues Surpass Estimates (Revised)

September 27, 2023 | Wall Street Fundamentals (Ad)

The "Plug and Play" Model Putting Online Giants to Shame

August 10, 2023 | msn.com

ProPhase Labs, Inc. (PRPH) Reports Q2 Loss, Lags Revenue Estimates

August 1, 2023 | finance.yahoo.com

Mundipharma International Corporation Limited, Mundipharma Medical Company, and Acrotech Biopharma Inc. Enter Agreement to Transfer License of FOLOTYN® (Pralatrexate) in China to CASI Pharmaceuticals

July 20, 2023 | finance.yahoo.com

Cleave Therapeutics Announces Acquisition of Clinical and Preclinical Assets

July 20, 2023 | finance.yahoo.com

CASI Pharmaceuticals Acquires Global Intellectual Property Rights to Cleave Therapeutics' VCP/P97 Inhibitor CB-5339

July 10, 2023 | finance.yahoo.com

Switch Therapeutics Appoints Douglas Fambrough, Ph.D., to Board of Directors

June 28, 2023 | finance.yahoo.com

CASI - CASI Pharmaceuticals, Inc.

May 28, 2023 | finance.yahoo.com

We Think CASI Pharmaceuticals (NASDAQ:CASI) Needs To Drive Business Growth Carefully

May 17, 2023 | finanznachrichten.de

CASI Pharmaceuticals, Inc. Announces First Quarter 2023 Financial Results

May 17, 2023 | finance.yahoo.com

CASI PHARMACEUTICALS ANNOUNCES FIRST QUARTER 2023 FINANCIAL RESULTS

May 3, 2023 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Aurinia Pharmaceuticals (AUPH) and Cytosorbents (CTSO)

April 26, 2023 | msn.com

CASI Pharmaceuticals GAAP EPS of -$3.01 misses by $2.64, revenue of $43.12M beats by $32.31M

April 26, 2023 | finance.yahoo.com

CASI Pharmaceuticals Files Annual Report on Form 20-F for Fiscal Year 2022

April 26, 2023 | finance.yahoo.com

CASI PHARMACEUTICALS ANNOUNCES FOURTH QUARTER AND FULL-YEAR 2022 FINANCIAL RESULTS

April 17, 2023 | finance.yahoo.com

Improved Revenues Required Before CASI Pharmaceuticals, Inc. (NASDAQ:CASI) Stock's 114% Jump Looks Justified

April 12, 2023 | benzinga.com

Will CASI Pharmaceuticals Inc (CASI) Outperform the Rest of the Stocks in the Healthcare Sector?

March 23, 2023 | marketwatch.com

Lisinopril Market Top Players and Forecast till 2031

March 22, 2023 | finanznachrichten.de

CASI Pharmaceuticals, Inc. Completes Redomiciliation Merger

March 17, 2023 | marketwatch.com

Hypoxia Inducible Factor 1 Alpha Inhibitor Market Size 2023 Research Report by Growth Rate Analysis and Forecast till 2027

See More Headlines

Receive CASI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for CASI Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

CASI Company Calendar

Last Earnings: 8/11/2023
Today: 9/27/2023
Next Earnings (Estimated): 11/13/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:CASI
CUSIP: N/A
CIK: 895051
Web: www.casipharmaceuticals.com
Phone: 861065086063
Fax: 301-315-2437
Employees: 224
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $10.00
High Stock Price Forecast: $10.00
Low Stock Price Forecast: $10.00
Forecasted Upside/Downside: +369.5%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($3.04)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-41,010,000.00
Net Margins: -93.92%
Pretax Margin: -85.72%
Return on Equity: -92.06%
Return on Assets: -41.99%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 5.12
Quick Ratio: 4.47

Sales & Book Value

Annual Sales: $43.11 million
Price / Sales: 0.66
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $3.28 per share
Price / Book: 0.65

Miscellaneous

Outstanding Shares: 13,322,000
Free Float: 10,492,000
Market Cap: $28.38 million
Optionable: Not Optionable
Beta: N/A

10 "Recession Proof" Stocks That Will Thrive in Any Market

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

Dr. Wei-Wu He Ph.D. (Age 58)
Chairman & CEO
Comp: $565.36k

Dr. Wei Zhang Ph.D. (Age 63)
Pres
Comp: $1.13M

Dr. Alexander A. Zukiwski M.D. (Age 66)
Exec. VP & Chief Medical Officer
Comp: $514.79k

Ms. Kun Qian (Age 41)
VP & Global Controller

Ms. Chunhua Wang (Age 51)
Chief Operating Officer

Ms. Wei Gao (Age 42)
Gen. Counsel

Dr. James E. Goldschmidt Ph.D.
Chief Bus. Devel. Officer

Mr. Fuqiang Zhang (Age 54)
Chief Commercial Officer

Ms. Amanda Cui
VP & Global Controller

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

CASI Stock - Frequently Asked Questions

Should I buy or sell CASI Pharmaceuticals stock right now?: 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for CASI Pharmaceuticals in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" CASI shares.
View CASI analyst ratings or view top-rated stocks.
What is CASI Pharmaceuticals' stock price forecast for 2023?: 2 equities research analysts have issued 12 month target prices for CASI Pharmaceuticals' stock. Their CASI share price forecasts range from $10.00 to $10.00. On average, they predict the company's share price to reach $10.00 in the next twelve months. This suggests a possible upside of 369.5% from the stock's current price.
View analysts price targets for CASI or view top-rated stocks among Wall Street analysts.
How have CASI shares performed in 2023?: CASI Pharmaceuticals' stock was trading at $1.79 at the beginning of the year. Since then, CASI shares have increased by 19.0% and is now trading at $2.13.
View the best growth stocks for 2023 here.
When is CASI Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, November 13th 2023.
View our CASI earnings forecast.
How were CASI Pharmaceuticals' earnings last quarter?: CASI Pharmaceuticals, Inc. (NASDAQ:CASI) announced its earnings results on Friday, August, 11th. The biotechnology company reported ($0.77) EPS for the quarter, missing the consensus estimate of ($0.50) by $0.27. The biotechnology company had revenue of $9.82 million for the quarter, compared to the consensus estimate of $10.09 million. CASI Pharmaceuticals had a negative net margin of 93.92% and a negative trailing twelve-month return on equity of 92.06%.
When did CASI Pharmaceuticals' stock split?: CASI Pharmaceuticals's stock reverse split before market open on Wednesday, June 1st 2022. The 1-10 reverse split was announced on Wednesday, June 1st 2022. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, June 1st 2022. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

What other stocks do shareholders of CASI Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other CASI Pharmaceuticals investors own include NVIDIA (NVDA), OPKO Health (OPK), Caladrius Biosciences (CLBS), Overstock.com (OSTK), Riot Platforms (RIOT), Boeing (BA), Enphase Energy (ENPH), Catalyst Pharmaceuticals (CPRX), Pure Storage (PSTG) and QUALCOMM (QCOM).
What is CASI Pharmaceuticals' stock symbol?: CASI Pharmaceuticals trades on the NASDAQ under the ticker symbol "CASI."
Who are CASI Pharmaceuticals' major shareholders?: CASI Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional shareholders include Geode Capital Management LLC (0.17%) and Northern Trust Corp (0.08%). Insiders that own company stock include James Huang, Weihao Xu and Wei-Wu He.
View institutional ownership trends.
How do I buy shares of CASI Pharmaceuticals?: Shares of CASI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is CASI Pharmaceuticals' stock price today?: One share of CASI stock can currently be purchased for approximately $2.13.
How much money does CASI Pharmaceuticals make?: CASI Pharmaceuticals (NASDAQ:CASI) has a market capitalization of $28.38 million and generates $43.11 million in revenue each year. The biotechnology company earns $-41,010,000.00 in net income (profit) each year or ($3.04) on an earnings per share basis.
How many employees does CASI Pharmaceuticals have?: The company employs 224 workers across the globe.
How can I contact CASI Pharmaceuticals?: CASI Pharmaceuticals' mailing address is 9620 MEDICAL CENTER DR STE 300, ROCKVILLE MD, 20850. The official website for the company is www.casipharmaceuticals.com. The biotechnology company can be reached via phone at 861065086063, via email at ir@casipharmaceuticals.com, or via fax at 301-315-2437.

This page (NASDAQ:CASI) was last updated on 9/27/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial